O'Brien, Susan <br/><br/>
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.  [electronic resource] 

 -  American journal of hematology  11 2018 
 - 1318-1326 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.25243  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Female<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Leukemia, Lymphocytic, Chronic, B-Cell--complications<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Purines--administration & dosage<br/>Remission Induction--methods<br/>Transaminases--drug effects<br/>Treatment Outcome